Greg Slabodkin

Chinese biopharma companies lead when it comes to manufacturing scale, CDMO capacity, and raw materials, according to analyses from the Cure Innovation Index.

The 120,000-liter Plant 1 facility at the CDMO's Songdo Bio Campus in Incheon is slated for full-scale commissioning and production system validation later this year.

In the space of three weeks, the company has announced four separate antibody-drug conjugate deals with AmMax Bio, Antharis Therapeutics, InduPro, and Stipple Bio.

Both CRDMOs were accused of ties to China's government, yet only WuXi AppTec was recently added to the Pentagon list of “Chinese military companies” operating in the U.S.

The Coalition for Epidemic Preparedness Innovations wants to leverage artificial intelligence to speed up the production of vaccines, but there are biosecurity risks.

With rising demand and the complexities of manufacturing oligo-based therapies, contract developers and manufacturers stand to benefit from the sector's expansion.

The most recent full-year data show a widening gap between the use of European and U.S. facilities, with the first half of 2026 continuing that trend, finds analytics firm.

On the heels of closing six facilities in 2025, the company has moved its headquarters from San Diego to Ohio with a biologics and aseptic drug product manufacturing focus.

The Indian drugmaker reported certain batches were out of specification due to an issue associated with the active pharmaceutical ingredient used in the product.

Funding trends, product pipelines, and the pace of R&D spending indicate demand is “poised to improve materially” for the rest of 2026, contend William Blair analysts.